Nota Informativa Importante su Betmiga (mirabegron) (07/09/2015)
L'Agenzia Italiana del Farmaco comunica nuove e importanti informazioni sull'uso di Betmiga (mirabegron).
Italiano
L'Agenzia Italiana del Farmaco comunica nuove e importanti informazioni sull'uso di Betmiga (mirabegron).
A pair of adverse reactions
Appropriate prescription of drugs in elderly patients is one of the biggest current challenges in clinical geriatrics. As is already known, the elderly often have multiple concomitant chronic conditions (multi-morbidities), which require the simultaneous use of multiple drugs (polypharmacy), which carries an increased risk of drug interactions and thus of adverse reactions.1
Earlier this year, at the presentation of the OsMed/AIFA report on drug consumption in Italy, health Minister Lorenzin expressed "grave concern at the increased consumption of opiates." Are Minister's concerns justified? Were we not the country with one of the lowest morphine consumption rates in the world? What has changed? Where did this "grave concern" come from?
Consumption in Italy
In Europe, according to the European Monitoring Centre (EMCDDA, 2013)1, 22% (70 million) of those aged between 15 and 64 years have used cannabis preparations (mainly marijuana) for recreational purposes at least once in their lifetime, 7% (23 million) within the last year, and 4% (14 million) within the last month. These percentages increase (17%) when considering use in the last year, in the age range 15-24 years.
A patient not receiving enough oxygen can result in possible injury or death.
If the ventilator shuts down, a patient may not receive necessary oxygen. This could cause patient injury or death.
80.211.154.110